"When Offered to Participate": A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials

Joseph M Unger, Dawn L Hershman, Cathee Till, Lori M Minasian, Raymond U Osarogiagbon, Mark E Fleury, Riha Vaidya, Joseph M Unger, Dawn L Hershman, Cathee Till, Lori M Minasian, Raymond U Osarogiagbon, Mark E Fleury, Riha Vaidya

Abstract

Background: Patient participation in clinical trials is vital for knowledge advancement and outcomes improvement. Few adult cancer patients participate in trials. Although patient.

decision-making about trial participation has been frequently examined, the participation rate for patients actually offered a trial is unknown.

Methods: A systematic review and meta-analysis using 3 major search engines was undertaken. We identified studies from January 1, 2000, to January 1, 2020, that examined clinical trial participation in the United States. Studies must have specified the numbers of patients offered a trial and the number enrolled. A random effects model of proportions was used. All statistical tests were 2-sided.

Results: We identified 35 studies (30 about treatment trials and 5 about cancer control trials) among which 9759 patients were offered trial participation. Overall, 55.0% (95% confidence interval [CI] = 49.4% to 60.5%) of patients agreed to enroll. Participation rates did not differ between treatment (55.0%, 95% CI = 48.9% to 60.9%) and cancer control trials (55.3%, 95% CI = 38.9% to 71.1%; P = .98). Black patients participated at similar rates (58.4%, 95% CI = 46.8% to 69.7%) compared with White patients (55.1%, 95% CI = 44.3% to 65.6%; P = .88). The main reasons for nonparticipation were treatment choice or lack of interest.

Conclusions: More than half of all cancer patients offered a clinical trial do participate. These findings upend several conventional beliefs about cancer clinical trial participation, including that Black patients are less likely to agree to participate and that patient decision-making is the primary barrier to participation. Policies and interventions to improve clinical trial participation should focus more on modifiable systemic structural and clinical barriers, such as improving access to available trials and broadening eligibility criteria.

© The Author(s) 2020. Published by Oxford University Press.

Figures

Figure 1.
Figure 1.
Selection of studies included in the analysis
Figure 2.
Figure 2.
Forest plots of the study-level and summary estimates for each domain. The boxes show the study-level estimate and the 95% confidence intervals. The overall effect is a summary measure for all trials combined. This is indicated by the dashed vertical line. CI = confidence interval.
Figure 3.
Figure 3.
Sensitivity analysis results for the “leave one out” method. Under this approach, each of the individual studies is left out of the calculation of the meta-analytic rate one at a time, and the rate is recalculated using the random-effects approach. Each panel shows the absolute percentage increase or decrease in the overall estimated rate for all trials, for treatment trials, and for cancer control trials, respectively. The primary estimates are also shown. The results are ordered in descending order from largest absolute positive percentage change to largest absolute negative percentage change.
Figure 4.
Figure 4.
Study specific estimates over time

References

    1. Institute of Medicine. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington, DC: National Academies Press; 2010.
    1. Murthy VH, Krumholz HM, Gross CP.. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–2726.
    1. Sateren WB, Trimble EL, Abrams J, et al.How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002;20(8):2109–2117.
    1. Tejeda HA, Green SB, Trimble EL, et al.Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst. 1996;88(12):812–816.
    1. Unger JM, Vaidya R, Hershman DL, et al.Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. J Natl Cancer Inst. 2019;111(3):245–255.
    1. Minasian LM, Unger JM.. What keeps patients out of clinical trials? J Clin Oncol Pract. 2020;16(3):125–127.
    1. Kim ES, Bruinooge SS, Roberts S, et al.Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J Clin Oncol. 2017;35(33):3737–3744.
    1. Go RS, Frisby KA, Lee JA, et al.Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer. 2006;106(2):426–433.
    1. Javid SH, Unger JM, Gralow JR, et al.A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). Oncologist. 2012;17(9):1180–1190.
    1. St Germain D, Denicoff AM, Dimond EP, et al.Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual. J Oncol Pract. 2014;10(2):e73–e80.
    1. Ford JG, Howerton MW, Lai GY, et al.Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008;112(2):228–242.
    1. Loree JM, Anand S, Dasari A, et al.Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870.
    1. Unger JM, Hershman DL, Osarogiagbon RU, et al.Representativeness of black patients in cancer clinical trials sponsored by the National Cancer Institute compared to pharmaceutical companies. JNCI Cancer Spectrum. 2020;4(4):pkaa034.
    1. Moher D, Liberati A, Tetzlaff J, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
    1. Viechtbauer W. Conducting meta-analyses in R with the metaphor package. J Stat Softw. 2010;36(3):1–48.
    1. Wang N. How to conduct a meta-analysis of proportions in r: a comprehensive tutorial. 2018; doi:10.13140/RG.2.2.27199.00161.
    1. Borenstein M, Hedges LV, Higgins JP, et al.A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Method. 2010;1(2):97–111.
    1. Brockwell SE, Gordon IR.. A comparison of statistical methods for meta-analysis. Stat Med. 2001;20(6):825–840.
    1. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10(1):101–129.
    1. Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T.. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974–978.
    1. DerSimonian R, Laird N.. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45(Pt A):139–145.
    1. Higgins JP, Thompson SG.. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
    1. Langan D, Higgins JPT, Jackson D, et al.A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. Res Syn Meth. 2019;10(1):83–98.
    1. Viechtbauer W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Educ Behav Stat. 2005;30(3):261–293.
    1. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR.. Introduction to Meta-Analysis. West Sussex: John Wiley & Sons, Ltd; 2009.
    1. Copur MS, Ramaekers R, Gönen M, et al.Impact of the National Cancer Institute Community Cancer Centers Program on clinical trial and related activities at a community cancer center in rural Nebraska. J Oncol Pract. 2016;12(67-8):e44-e51.
    1. Petrelli NJ. A community cancer center program: getting to the next level. J Am Coll Surg. 2010;210(3):261–270.
    1. Pfister DG, Rubin DM, Elkin EB, et al.Risk adjusting survival outcomes in hospitals that treat patients with cancer without information on cancer stage. JAMA Oncol. 2015;1(9):1303–1310.
    1. Begg CB, Mazumdar M.. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101.
    1. Guarino MJ, Masters GA, Schneider CJ, et al.Barriers exist to patient participation in clinical trials. J Clin Oncol. 2005;23(suppl 16):6015–6015.
    1. Tennapel MJ, Chen AM, Shen X.. Clinical trial accrual patterns for radiation oncology patients at an academically based tertiary care medical center. Int J Rad Oncol Biol Phys. 2017;99(2):e418.
    1. Dayao Z, Nemunaitis J. Abstract P5-13-06: Analysis of barriers to clinical trial accrual in an NCI-designated comprehensive cancer center: Results of identifying clinical trial gaps. San Antonio Breast Cancer Symposium Proceedings. 2019. ;79(suppl 4):P5-13-06.
    1. Grubbs SS, Gonzalez M, Krasna M, et al.Tracking clinical trial accrual strategies and barriers via a Web-based screening tool. J Clin Oncol. 2009;27(suppl 15):6586.
    1. Adams-Campbell LL, Ahaghotu C, Gaskins M, et al.Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol. 2004;22(4):730–734.
    1. Albrecht TL, Eggly SS, Gleason ME, et al.Influence of clinical communication on patients’ decision making on participation in clinical trials. J Clin Oncol. 2008;26(16):2666–2673.
    1. Aycinena AC, Valdovinos C, Crew KD, et al.Barriers to recruitment and adherence in a randomized controlled diet and exercise weight loss intervention among minority breast cancer survivors. J Immigrant Minority Health. 2017;19(1):120–129.
    1. Baggstrom MQ, Waqar SN, Sezhiyan AK, et al.Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials. J Thorac Oncol. 2011;6(1):98–102.
    1. Bernard-Davila B, Aycinena AC, Richardson J, et al.Barriers and facilitators to recruitment to a culturally-based dietary intervention among urban Hispanic breast cancer survivors. J Racial Ethn Health Disparities. 2015;2(2):244–255.
    1. Biedrzycki BA. Factors and outcomes of decision making for cancer clinical trial participation. Oncol Nurs Forum. 2011;38(5):542–552.
    1. Brooks SE, Carter RL, Plaxe SC, et al.Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study. Gynecol Oncol. 2015;138(1):101–108.
    1. Dignan M, Evans M, Kratt P, et al.Recruitment of low income, predominantly minority cancer survivors to a randomized trial of the I Can Cope cancer education program. J Health Care Poor Underserved. 2011;22(3):912–924.
    1. Fu S, McQuinn L, Naing A, et al.Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist. 2013;18(12):1315–1320.
    1. Grant CH 3rd, Cissna KN, Rosenfeld LB.. Patients’ perceptions of physicians communication and outcomes of the accrual to trial process. Health Commun. 2000;12(1):23–39.
    1. Greenwade MM, Moore KN, Gillen JM, et al.Factors influencing clinical trial enrollment among ovarian cancer patients. Gynecol Oncol. 2017;146(3):465–469.
    1. Horn L, Keedy VL, Campbell N, et al.Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin Lung Cancer. 2013;14(1):14–18.
    1. Jirka GW, Bisselou KSM, Smith LM, et al.Evaluating the decisions of glioma patients regarding clinical trial participation: a retrospective single provider review. Med Oncol. 2019;36(4):34.
    1. Kanarek NF, Kanarek MS, Olatoye D, et al.Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study. Trials. 2012;13(1):237.
    1. Kemeny MM, Peterson BL, Kornblith AB, et al.Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003;21(12):2268–2275.
    1. Krieger JL, Palmer-Wackerly A, Dailey PM, et al.Comprehension of randomization and uncertainty in cancer clinical trials decision making among rural, Appalachian patients. J Canc Educ. 2015;30(4):743–748.
    1. Langford AT, Resnicow K, Dimond EP, et al.Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute’s Community Cancer Centers Program. Cancer. 2014;120(6):877–884.
    1. Lara PN Jr, Higdon R, Lim N, et al.Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19(6):1728–1733.
    1. Logan JK, Tang C, Liao Z, et al.Analysis of factors affecting successful clinical trial enrollment in the context of three prospective, randomized, controlled trials. Int J Radiat Oncol Biol Phys. 2017;97(4):770–777.
    1. Martel CL, Li Y, Beckett L, et evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. Cancer J. 2004;10(5):294–300.
    1. Moore DH, Kauderer JT, Bell J, et assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;94(2):368–374.
    1. Penberthy L, Brown R, Wilson-Genderson M, et al.Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment. Clin Trials. 2012;9(6):788–797.
    1. Sears SR, Stanton AL, Kwan L, et al.Recruitment and retention challenges in breast cancer survivorship research: results from a multisite, randomized intervention trial in women with early stage breast cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(10):1087–1090.
    1. Siminoff LA, Zhang A, Colabianchi N, et al.Factors that predict the referral of breast cancer patients onto clinical trials by their surgeons and medical oncologists. J Clin Oncol. 2000;18(6):1203–1211.
    1. Simon MS, Du W, Flaherty L, et al.Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol. 2004;22(11):2046–2052.
    1. Swain-Cabriales S, Bourdeanu L, Niland J, et al.Enrollment onto breast cancer therapeutic clinical trials: a tertiary cancer center experience. Appl Nurs Res. 2013;26(3):133–135.
    1. Umutyan A, Chiechi C, Beckett LA, et al.Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Cancer. 2008;112(1):212–219.
    1. Unger JM, Hershman DL, Albain KS, et al.Patient income level and cancer clinical trial participation. J Clin Oncol. 2013;31(5):536–542.
    1. Zafar SF, Heilbrun LK, Vishnu P, et al.Participation and survival of geriatric patients in phase I clinical trials: the Karmanos Cancer Institute (KCI) experience. J Geriatr Oncol. 2011;2(1):18–24.
    1. Public Citizen Health Research Group. Unsettling scores: a ranking of state Medicaid programs. 2007. . Accessed June 6, 2020.
    1. American Cancer Society Cancer Action Network. Medicaid: Ensuring Access to affordable health care coverage for lower income cancer patients and survivors. 2020. . Accessed June 6, 2020.
    1. Library of Congress. HR 6836—Clinical Treatment Act. 115th Congress (2017-2018). . . Accessed June 6, 2020.
    1. Borno HT, Zhang L, Siegel A, et what cost to clinical trial enrollment? A retrospective study of patient travel burden in cancer clinical trials. Oncologist. 2018;23(10):1242–1249.
    1. Bristow RE, Chang J, Ziogas A, et al.Spatial analysis of adherence to treatment guidelines for advanced-stage ovarian cancer and the impact of race and socioeconomic status. Gynecol Oncol. 2014;134(1):60–67.
    1. Henley SJ, Anderson RN, Thomas CC, et al.Invasive cancer incidence, 2004-2013, and deaths, 2006-2015, in nonmetropolitan and metropolitan counties—United States. MMWR Surveill Summ. 2017;66(14):1–13.
    1. Campbell NC, Ritchie LD, Cassidy J, et al.Systematic review of cancer treatment programmes in remote and rural areas. Br J Cancer. 1999;80(8):1275–1280.
    1. US Food and Drug Administration. FDA Guidance on conduct of clinical trials of medical products during COVID-19 pandemic. 2020. . Accessed June 5, 2020.
    1. National Cancer Institute. Coronavirus guidance. 2020. . Accessed June 6, 2020.
    1. Schrag D, Hershman DL, Basch E.. Oncology practice during the COVID-19 pandemic. JAMA. 2020;323(20):2005.
    1. Esmail L, Moore E, Rein A.. Evaluating patient and stakeholder engagement in research: moving from theory to practice. J Comp Eff Res. 2015;4(2):133–145.
    1. Ramsey SD, Barlow WE, Gonzalez-Angulo AM, et al.Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials. 2013;34(1):1–9.
    1. Unger JM, Moseley A, Symington B, et al.Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials. JAMA Netw Open. 2018;1(4):e181235.
    1. National Cancer Institute. Community Oncology Research Program. . Accessed June 7, 2020.
    1. American Cancer Society Cancer Action Network. Letter to Dr. Normal E. Sharpless, Director, National Cancer Institute. Re: NCI Request for Information, Strategies for Matching Patients to Clinical Trials (NOT-CA-18-063). 2018. Comments%20on%20NCI%20RFI%20%20NOT-CA-18-063%2006.15.2018%20-%20FINAL_0.pdf. Accessed June 7, 2020.
    1. American Society of Clinical Oncology. ASCO in Action: initiative to modernize eligibility criteria for clinical trials launched. 2016. . Accessed October 19, 2020.
    1. Unger JM, Hershman DL, Fleury ME, et al.Association of patient comorbid conditions with cancer clinical trial participation. JAMA Oncol. 2019;5(3):326–333.
    1. Harvey RD, Rubinstein WS, Ison G, et al.Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: real-world analysis. J Clin Oncol. 2019;37(suppl 18).
    1. Byrne MM, Tannenbaum SL, Glück S, et al.Participation in cancer clinical trials: why are patients not participating? Med Decis Making. 2014;34(1):116–126.
    1. Gross CP, Filardo G, Mayne ST, et al.The impact of socioeconomic status and race on trial participation for older women with breast cancer. Cancer. 2005;103(3):483–491.
    1. Wendler D, Kington R, Madans J, et al.Are racial and ethnic minorities less willing to participate in health research? PLoS Med. 2005;3(2):e19.
    1. Kanarek NF, Tsai HL, Metzger-Gaud S, et al.Geographic proximity and racial disparities in cancer clinical trial participation. J Natl Compr Canc Netw. 2010;8(12):1343–1351.
    1. Shavers VL, Brown ML.. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334–357.
    1. Hamel LM, Penner LA, Albrecht TL, et al.Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Control. 2016;23(4):327–337.
    1. Nelson A. Unequal treatment: confronting racial and ethnic disparities in health care. J Natl Med Assoc. 2002;94(8):666–668.
    1. Gotay CC. Accrual to cancer clinical trials: directions from the research literature. Soc Sci Med. 1991;33(5):569–577.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner